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Background: Manipulation under anaesthesia (MUA) or arthroscopic capsular release (ACR), 
are costly and invasive treatments for frozen shoulders but their effectiveness remains 
uncertain. We compared these two surgical interventions with early structured 
physiotherapy plus steroid injection (ESP).  
 
Methods: A pragmatic, non-blinded, parallel group, three-arm trial in 35 hospitals across the 
United Kingdom. Participants were adults with unilateral frozen shoulder, characterised by 
restriction of passive external rotation in the affected shoulder to less than 50% of the 
opposite shoulder. Participants were randomly assigned to MUA:ACR:ESP in the ratio of 
2:2:1. The primary outcome was the Oxford Shoulder Score (OSS) at 12 months post-
randomisation, analysed by intention-to-treat. We sought a target difference of five OSS 
points between ESP and MUA or ACR, or four points between MUA and ACR. The trial 
registration is ISRCTN48804508. 
 
Findings: Between April 2015 and December 2017, we randomly assigned 503 participants 
to treatment groups (99 to ESP; 201 to MUA; 203 to ACR). Follow-up was completed in 
January 2019. At 12 months, OSS data were available for 93 participants assigned to ESP 
(mean estimate 37·2); 189 to MUA (38·3); and 191 to ACR (40·3). Mean group differences at 
12 months were 2·01 points between participants randomised to ACR and MUA (95% 
confidence interval (CI) 0·10 to 3·91), 3·06 points between ACR and ESP (95% CI 0·71 to 
5·41), and 1·05 points between MUA and ESP (95% CI -1·28 to 3·39). Eight serious adverse 
events were reported with ACR and two with MUA. At a £20,000 per Quality-Adjusted Life 
Year willingness-to-pay threshold, MUA had the highest probability of being cost-effective 
(0·8632) then ESP (0·1366) and ACR (0·0002). 
 
Interpretation:  
All of the mean differences on the assessment of shoulder pain and function (OSS) at the 
primary endpoint of 12 months were less than the target differences. Therefore, none of 
the three interventions were clinically superior. ACR carried higher risks. MUA was the cost-
effective option.  
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Research in Context: 
 
Evidence Before this study:  
Frozen shoulder is a common and painful condition where movements in the shoulder 
become restricted. Whilst it is often a self-limiting condition, there may be slow and 
incomplete resolution during which people may struggle with basic daily activities, work and 
have disturbed sleep from the pain. Generally, conservative treatments are provided in a 
primary care setting in the UK. More invasive, surgical treatments, such as MUA or 
arthroscopic capsular release (ACR), are used in hospital.  
 
In 2012, we published a NIHR HTA programme funded systematic review of 28 randomised 
controlled trials (RCT), one quasi-experimental study, and two case series. Nineteen 
databases and sources including CINAHL, Science Citation Index, BIOSIS Previews and DARE 
were searched up to March 2010 and EMBASE and MEDLINE up to January 2011, without 
any language restrictions. The review concluded that there was limited evidence on the 
clinical and cost-effectiveness of different treatment options in the management of a 
primary frozen shoulder, including intensive or invasive interventions. The need for high 
quality primary research was recommended.  
 
The findings of our national survey of 303 health care professionals in the UK (conducted in 
2010) determined that Physiotherapy, MUA and ACR were the more frequently used 
interventions in a secondary care setting that needed comparing within an RCT. Only 6% of 
respondents at the time suggested Hydrodilatation as a comparator for an RCT. Early 
Structured Physiotherapy (ESP) was a multi-component secondary care physiotherapy 
intervention including steroid injection that we developed using recommendations from 
national guidelines and a Delphi study of shoulder specialist physiotherapists. We then 
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conducted a randomised, pragmatic, non-blinded, parallel, three-arm, superiority trial called 
UK FROST to determine the clinical (pain and function) and cost-effectiveness of ESP 
compared with MUA; ESP compared with ACR; and MUA compared with ACR. 
 
Added value of this study: 
To our knowledge, UK FROST is the largest randomised trial including 503 participants that 
compared ESP, MUA and ACR. Surgical interventions (MUA or ACR) did not have better 
clinically important outcomes for shoulder pain and function compared with ESP at 12 
months. ACR carried higher risks. ESP was a low-cost option which could be accessed 
quicker but was not clinically superior. The health economic comparison found MUA to be 
the most cost-effective intervention within the UK healthcare setting. Our embedded 
qualitative study identified early medical help and quicker access to NHS care pathways was 
important to patients. 
 
A focused update of the 2012 systematic review using searches until December 2018 
assembled the current evidence of RCTs for the effectiveness of interventions evaluated in 
UK FROST. Hydrodilatation was included because of evidence of its increasing popularity in 
spite of a paucity of evidence. Nine trials (including UK FROST) were included with the 
number of participants in other trials ranging from 26 to 136. The quality of the included 
trials was variable and considerable heterogeneity of the interventions made it difficult to 
combine studies or draw conclusions. Only two trials were pooled in a meta-analysis, UK 
FROST and another trial, which compared long term functioning between ACR and 
physiotherapy plus steroid injection. The pooled effect favoured ACR (SMD 0.32, 95% CI 
0.08, 0.56), but was smaller in magnitude than the clinical threshold of the standard effect 
size used in UK FROST. Evidence of Hydrodilatation’s effectiveness from four trials was 
inconclusive. 
 
Implications of all the available evidence:  
UK FROST provides robust evidence confirming that none of the three trial treatments were 
superior on patient-reported outcomes for shoulder pain and function at 12 months. There 
could be, however, a potentially marginal clinically important benefit in the wider 
population in favour of ACR compared with ESP. Our specifically designed ESP pathway with 
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a steroid injection was accessed quicker than the other treatment options and is lower in 
cost; therefore, its potential for implementation into clinical practice to the same standards 
as in the trial should be carefully considered. Importantly MUA was the most cost-effective 
option. This was because the modest additional cost for an MUA to maximise patients’ 
health-related quality of life would be considered good value for money to the UK NHS at 
the NICE threshold of willingness-to-pay. MUA is an existing pathway in the NHS and 
requires limited use of theatre time compared with ACR. ACR also carries higher risks and 
costs compared with MUA and ESP but fewer participants allocated to this group required 
further treatment for their frozen shoulder. The evidence suggests ACR should be used 
more selectively, when less costly and less invasive interventions fail. These treatment 
options should be discussed between patients and clinicians in shared decision-making. 
Further evaluation is recommended to address the increasing popularity of Hydrodilatation 




Frozen shoulder, also known as adhesive capsulitis, is a painful condition that most 
commonly affects people in the sixth decade of life.1 2 The capsule of the shoulder joint 
becomes inflamed, then scarred and contracted causing pain, stiffness and loss of function.3 
People with frozen shoulder may struggle with basic daily activities and have sleep 
disturbance due to shoulder pain.4 The cumulative incidence of frozen shoulder is estimated 
at 2·4 per 1000 population per year,1 affecting 8·2% of men and 10·1% of women of working 
age.2 The exact cause remains unknown, which is why it is often labelled ‘idiopathic’ or 
‘primary’ frozen shoulder. Recognised associations include diabetes mellitus, cardiovascular 
disease, trauma, stroke, neuro-surgery and thyroid disease. Association with diabetes 
mellitus is considered to make it more resistant to treatment.5 
 
Diagnosis of frozen shoulder is based on clinical features of insidious onset deep seated pain 
in the shoulder and upper arm with increasing stiffness and clinical findings of limited active 
and passive external rotation in the absence of crepitus.6 X-rays are not routinely required,7 
but may be performed to exclude shoulder arthritis or posterior dislocation that could 




Frozen shoulder can spontaneously resolve, but recovery may be slow or incomplete. 
Around 40% of patients report persistent symptoms even after four years from onset.8 
Primarily, the severity of pain and disability arising from restriction of movement drives 
patients to seek treatment.4 A range of treatment options with increasing degrees of 
invasiveness are available, but there is uncertainty about when these should be offered, and 
their clinical or cost-effectiveness.9 A survey of specialist health professionals that we 
conducted in the United Kingdom (UK) identified three interventions as being most 
commonly used: Physiotherapy; Manipulation Under Anaesthesia (MUA); and Arthroscopic 
Capsular Release (ACR).10 The UK national physiotherapy guidelines for frozen shoulder, 
based on a systematic review, recommends exercise and manual therapy either in isolation; 
or to supplement intra-articular injection of glucocorticoid (steroid), MUA or ACR.11 We 
further developed and standardised the non-surgical care pathway for this trial to include 
intra-articular steroid injection followed by structured physiotherapy using the best 
available evidence and consensus from expert shoulder physiotherapists. We called this 
‘Early’ Structured Physiotherapy (ESP) as it is more quickly accessible within secondary care 
than the surgical interventions.12 It is not known whether ESP, or either of the surgical 
interventions (MUA or ACR) followed by physiotherapy is more effective.13 Systematic 
reviews have identified large gaps in evidence and a need for high quality primary 
research.13 14 With the intention of facilitating quicker recovery, MUA and ACR are 
increasingly used in spite of lack of good evidence.13 15  
 
We designed the UK Frozen Shoulder Trial (UK FROST) to assess the effectiveness and cost-
effectiveness of three care pathways to treat adults with a frozen shoulder: two commonly 
used surgical interventions within the UK National Health Service (NHS) hospitals (MUA and 




Study design  
Our detailed study protocol has been published.16 We conducted a multicentre, 
randomised, pragmatic, superiority trial comparing three parallel groups (ESP versus MUA 
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versus ACR) for patients referred to secondary care for treatment of primary frozen 
shoulder. The trial recruited from 35 hospital sites in the UK; 90 surgeons and 285 
physiotherapists, who were experienced in using these treatments, delivered the trial 
interventions. Two additional hospitals screened patients but did not recruit to the trial.  
 
Ethics approval was obtained on 18 November 2014 from the National Research Ethics 
Service (NRES Committee North East – Newcastle & North Tyneside 2; Research Ethics 
Committee Reference 14/NE/1176). Local site-specific NHS research and development 
approvals were obtained from each participating site. The study was adopted to the UK 
Clinical Research Network portfolio (17719). 
 
Participants 
Patients referred to participating NHS hospitals were eligible if they were 18 years or older 
and presented with a clinical diagnosis of unilateral frozen shoulder characterised by 
restriction of passive external rotation (50% or more) in the affected shoulder17 for which 
there is evidence of good inter-rater agreement.18 Plain radiographs (antero-posterior and 
axillary view) of the affected shoulder were obtained to exclude other pathology. Detailed 
exclusion criteria are in the protocol, which included bilateral concurrent frozen shoulders; 
secondary causes (other than diabetes); and if any of the trial treatments were 
contraindicated. Patients with diabetes were included, as this is significantly associated with 
impaired shoulder mobility in this patient population.19 Informed consent was obtained 
from all trial participants by suitably qualified local study personnel at each participating 
site. 
 
Randomisation and masking 
Surgeons or physiotherapists confirmed eligibility. Following collection of baseline data for 
eligible and consenting patients, the research nurse accessed a secure remote 
randomisation service via telephone or internet provided by a registered clinical trials unit 
at the University of York.  Individual participants were randomly assigned with unequal 
allocation (2:2:1) to ACR, MUA, or ESP to allow for different sought effect sizes between 
groups. Allocation was based on a computer generated randomisation algorithm that used 
random block sizes of 10 and 15 and stratified by presence of diabetes. Registering 
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participants before remote computer-generated randomisation with randomly varying block 
sizes ensured concealment. 
 
Blinding of participants and clinicians to treatment allocation was not possible or desirable 
in this pragmatic trial. Therefore, participants and clinicians were informed about treatment 




Participants underwent standardised physiotherapy programmes in all three arms of the 
trial. ESP and post-procedural (following MUA and ACR) physiotherapy programmes were 
standardised using evidence from a systematic review,13 UK guidelines, previous surveys of 
UK Physiotherapists and Delphi consensus methodology.20 The full, standard course of ESP 
and post-procedural physiotherapy was 12 sessions over up to 12 weeks. If the 
physiotherapist and participant were satisfied with their progress, not all 12 sessions were 
necessary; but otherwise, participants were encouraged to attend the full, standard course. 
In the ESP intervention, the intra-articular steroid (glucocorticoid) injection before starting 
physiotherapy was administered with or without imaging guidance depending on usual 
practice of the hospital site, as current evidence did not support superiority of either 
approach.21 Full details about the ESP and post-procedural physiotherapy programmes are 
detailed elsewhere.12 16  
 
MUA and ACR were performed as day case surgical procedures. With MUA, the surgeon 
manipulated the affected shoulder in a controlled fashion to stretch and tear the tight 
capsule when the participant was under general anaesthesia; and that was supplemented 
by an intra-articular steroid injection. If the MUA was judged to be incomplete, the surgeon 
did not cross-over intra-operatively to do ACR in order to allow assessment of outcome of 
the MUA. ACR was performed under general anaesthesia by a surgeon to surgically divide 
the contracted anterior capsule in the rotator interval; and was supplemented with MUA to 
complete and confirm optimal capsular release. Additional procedures like posterior 
capsular release were permitted at the discretion of the operating surgeon and were 
recorded. Both MUA and ACR were followed by post-procedural physiotherapy. All 
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participants were provided with instructions on a graduated home exercise programme 
progressing from gentle pendular exercises to firm stretching exercises according to stage of 
frozen shoulder, as is accepted good practice.11 20 
 
All interventions were delivered by participating surgeons who were familiar with the 
surgical procedures and by qualified physiotherapists (i.e. not students or assistants). There 
was no minimum number of surgical procedures that the surgeon had to have performed 
and no grades of surgeon were excluded. No additional training was required for either 
programme of physiotherapy. 
 
Outcomes 
The primary outcome was the Oxford Shoulder Score (OSS), a 12-item patient-reported 
outcome measure of shoulder pain and function with five response categories and an 
overall scale ranging from 0 (worst) to 48 (best).22 The primary end-point was 12 months 
after randomisation. 
 
Secondary patient-reported outcome measures were QuickDASH (Disabilities of the Arm, 
Shoulder and Hand)23 as a further region-specific measure of response to treatment;24 
health related-quality of life using the EQ-5D-5L (5 Level version);25 NRS (Numeric Rating 
Scale) for pain;26 and perceived extent of recovery measured by a single VAS (Visual 
Analogue Scale) ranging from 0 to 100 (0 – no need / 100 - definite need to seek further 
treatment). The VAS about treatment recovery was purposefully designed for the study with 
input from patients and clinicians. All outcome measures were collected at baseline, three, 
six and 12 months after randomisation. In addition, OSS was collected at start of treatment 
and six months post treatment. Any complications and adverse events were recorded. 
Following completion of the allocated intervention, any further treatments for the frozen 
shoulder were recorded. 
 
A full description of the sample size calculation and statistical analysis plan is in the 
published protocol.16 The sample size was based on the primary outcome measure (OSS) at 
12 months after randomisation and was calculated using a minimum clinically important 
difference of five points when comparing ESP with either surgical treatment; or a difference 
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of four points when comparing the two surgical treatments. The larger difference when 
comparing ESP with a surgical treatment was required to justify the greater costs and 
potential risks associated with surgery.22 To observe the above differences with 90% power 
and 5% two-sided significance, adjusting for a conservative estimate (r=0·4) of the 
correlation between OSS over 12 months and allowing for 20% loss to follow up, a total 
sample size of 500 patients was required (MUA:200, ACR:200, ESP:100). No adjustment was 
made for multiple comparisons, owing to the a priori specified sequence of treatment 
comparisons (MUA vs ESP, ACR vs ESP, MUA vs ACR; results were interpreted as if from 
three independent trials, with inference for one comparison not dependent on the outcome 
of another).27  
 
Statistical analysis 
The analysis of primary and secondary outcomes followed intention–to-treat (ITT) principles 
(comparisons according to the randomised group, irrespective of compliance, without 
imputation for minimal missing data). A linear mixed model incorporating all time points 
and using an unstructured covariance pattern was used. The model adjusted for age (in 
years), gender (male / female), diabetes status (diabetic / non-diabetic), and OSS at baseline 
as fixed effects and recruitment site (35 sites) as a random effect. A single model was used 
for the analysis, and treatment group differences at each time point were presented as 
three separate two-way comparisons (i.e. MUA vs ESP; ACR vs ESP; and ACR vs MUA). The 
OSS at 12 months, QuickDASH, pain NRS, and extent of recovery VAS were analysed in a 
similar manner. 
 
To address the impact of delays in receiving the allocated treatment, a separate secondary 
intention to treat linear mixed model incorporated time as a continuous variable, including 
data from all available time points for each participant (additionally including pre-treatment 
and 6 months post-treatment OSS scores) and adjusting for the same covariates as the 
primary analysis model. Treatment effect estimates were extracted at three, six and 12 
months post-randomisation. 
 
Complier Average Causal Effect (CACE) analysis investigated the effect of adherence with 
ESP on the OSS at 12 months using instrumental variable regression. Additional sensitivity 
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analyses included additional adjustment for predictors of missing data, exclusion of 
response data received beyond six weeks of each intended follow-up and adjustment for 
observed baseline differences in employment status. Subgroup analyses explored whether 
the treatment response was influenced by presence of diabetes, prior physiotherapy 
treatment and participant treatment preference at baseline by including treatment by sub-
group interactions in the model. Adverse events and complications were listed by allocated 
group and compared by chi-squared test.  
 
All statistical testing was done at the two-sided 5% significance level and estimates given 
with 95% Confidence Intervals (CIs) using Stata 15. The statistical analysis plan was 
approved by an independent data monitoring committee and the trial steering committee. 
The trial is registered with the International Standard Randomised Controlled Trial Register, 
ID: ISRCTN48804508. 
 
Health economic analysis 
Economic analyses were conducted in accordance with the National Institute for Health and 
Care Excellence (NICE) reference case standards.28 The base-case analysis was conducted on 
an ITT basis with multiple imputation for missing data, which was assumed missing at 
random. The analysis was conducted from an NHS and Personal Social Services perspective 
and included the cost of the initial intervention, hospital stays and outpatient appointments 
after initial intervention and visits to primary and community health care professionals over 
one year. Costs were calculated using National UK unit costs and expressed in British Pound 
Sterling (GBP) at the 2018 price. Outcomes were measured in terms of quality-adjusted life 
year (QALYs) over one year. We used a mapping function to derive utilities,29 30 and the Area 
Under the Curve method to estimate QALYs.  
 
Differences in mean costs and mean QALYs at 12 months were used to derive the 
incremental cost-effectiveness ratios (ICERs), which represents the greater benefit per GBP 
spent. This was estimated by comparing mean differences in expected costs and QALYs 
between treatment groups. The mean estimates and their 95% CI were generated by means 
of seemingly unrelated regression (SUR). Decisions about whether a treatment is efficient or 
not (i.e. value for money) are determined as to whether the cost per QALY gained (i.e. ICER) 
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is below some threshold value. The threshold represents the opportunity cost of delivering 
an intervention (i.e. the health forgone from providing this intervention). At present, NICE 
threshold ranges between £20,000 and £30,000 per QALY. According to the current 
established decision rules, if the estimated cost per QALY is below the £20,000 threshold, 
the intervention would be considered cost-effective in terms of QALYs gained.  
 
In order to compute the probability of each intervention being cost-effective, the SUR was 
conducted within a bootstrapping approach on five imputed data sets to generate 10,0000 
replicates of incremental costs and benefits. The probability that each intervention is cost-
effective is reported at the cost-effectiveness threshold applied by NICE of £20,000 to 
£30,000/QALY, and a further recommended threshold of £13,000/QALY.31 32  
 
Role of the funding source 
The funders monitored the trial progress but had no role in study design, data collection, 
data analysis, data interpretation, or writing or approving or the decision to submit the 
publication. The corresponding author had full access to all the data in the study and had 




Between April 2015 and December 2017, we randomly assigned 503 patients (out of 914 
screened patients with a frozen shoulder) to receive the following treatments: 201 to MUA, 
203 to ACR and 99 to ESP (Figure 1). Baseline characteristics as randomised and as analysed 
in the three groups have been presented (Table 1).  
 
Within the allocated treatment groups, 82% of participants (n=164) completed MUA, 80% 
completed ACR (n=162) and 81% completed ESP (n=80). There were also 82% of participants 
(n=164) who had a steroid injection in the MUA group, 22% in the ACR group (n=45) and 
80% in the ESP group (n=79). Further details about the delivery, type and dose of the steroid 
are provided in the Supplementary Material. Sixteen participants (3%) crossed over to a 
different trial treatment, and 17 (3%) received an alternative treatment. Overall, 64 
participants (13%) did not receive any treatment. Waiting times to the start of each 
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randomised treatment varied considerably. Participants waited a median of 14 days (IQR 7 
to 22) for ESP, median of 56·5 days (IQR 34·5 to 88·5) for MUA, and a median of 71·5 days 
(IQR 42 to 116) for ACR (Supplementary material). Following completion of their 
randomised treatment, a number of participants received further treatment (Table 2). The 
highest number of further treatments were received by participants in the ESP arm (15%, 
n=15); fewer by MUA participants (7%, n=14) and the fewest further treatments by ACR 
participants (4%, n=8). 
 
At the primary end point at 12 months, many participants improved to nearly full shoulder 
functioning (median overall OSS of 43 out of 48 points). Participants randomised to ACR had 
on average statistically significantly higher (better) OSS scores than MUA (40·3 versus 38·3 
points, difference: 2·01, 95% CI 0.10 to 3·91) and ESP (40·3 versus 37·2 points, difference: 
3·06 points, 95% CI 0·71 to 5·41). MUA had higher mean OSS than ESP (38·3 versus 37·2 
points, difference: 1.05, 95% CI -1.28 to 3.39) (raw means in Figure 2). Mean estimates were 
short of the minimal clinically important effect size of four to five OSS points (Table 3). For 
the short-term follow-up at three months post-randomisation, ACR had lower (worse) 
outcomes compared with the other two interventions. Differences of clinically important 
magnitude as defined above were included in the 95% CIs for the benefit of MUA and ESP 
compared with ACR at three months and ACR compared with ESP at 12 months.  
 
Compared with the primary analysis, group differences in the model adjusted for waiting 
times tended to be of smaller magnitude, with the exception of the difference between ACR 
and ESP at 12 months (3.26 points in favour of ACR, 95% CI 1·18 to 5·35) (Supplementary 
material). From the CACE analysis, outcomes for participants who adhered to ESP treatment 
remained lower than for participants in other treatment arms (-1·84 OSS points, 95% CI -
4·41 to 0.74), although the difference was not statistically significant. Predictors of 
missingness were age and OSS outcomes prior to being missing. These are already 
incorporated in the primary analysis. Sensitivity analyses regarding the timing of 
questionnaire return and adjustment for employment status did not show marked 




Of the secondary outcomes, QuickDASH and shoulder pain followed a similar pattern to the 
OSS with significantly poorer outcomes for ACR participants at three months but better 
outcomes at 12 months post-randomisation compared with MUA or ESP. There were no 
clear group differences in extent of recovery based on the treatment-seeking VAS. 
 
In total, there were ten serious adverse events (SAEs), reported for nine participants, of 
whom eight were in the ACR group (4%) and two in the MUA group (1%). There was one 
participant in the ACR group who had an SAE from non-trial physiotherapy (Table 4). 
Numbers were insufficient for formal analysis. There were 33 non-serious adverse events, 
reported for 31 participants with comparable rates in the three arms (n=14 / 7% of MUA 
patients, n=12 / 6% of ACR patients and n=5 / 5% of ESP patients). There was no evidence 
for statistical differences in the proportion of non-serious adverse events (p=0·19). 
 
The base-case economic analysis, with multiple imputation, showed that MUA was £276 
(95% CI £65·67 to £487·35) more expensive per participant than ESP. ACR was substantially 
more costly than ESP [on average £1,733.78 more per participant (95% CI 1,529·48 to 
1,938·06)] and MUA [£1,457·26 more per participant (95% CI 1,282·73 to 1,631·79)]. Overall, 
ACR had worse QALYs compared with MUA (mean difference -0·0293; 95% CI -0·0616 to 
0·0030) and MUA had better QALYs compared with ESP (mean difference 0·0396; 95% CI -
·0008 to 0·0800). MUA was the intervention most likely to be cost-effective at a £20,000 per 




UK FROST is the largest randomised clinical trial to date that evaluated common surgical 
interventions and a specifically designed Physiotherapy pathway with a steroid injection 
(ESP) for the treatment of adults with a frozen shoulder in the UK NHS. Patient-reported 
shoulder pain and function improved significantly from baseline with all three trial 
treatments. At the primary endpoint of 12 months, the magnitude of difference of ACR over 
MUA and ESP was statistically significant but unlikely to be clinically important. This finding 
was consistent for all patient reported clinical outcomes. ACR was associated with higher 
risks. MUA  was the most cost-effective option. A detailed economic evaluation of relative 
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cost-effectiveness of the three treatment options will be published separately, but key 
results have been included as they are integral to interpreting the main clinical effectiveness 
findings. 
 
The differences in patient reported outcomes between the treatment groups seen at three 
months were influenced by longer waiting times (13% of MUA participants and 23% of ACR 
participants commenced treatment after the three-month follow-up) for the surgical 
interventions. The planned analysis of our primary outcome, the Oxford Shoulder Score 
(OSS), adjusted for variable waiting times between the three interventions using additional 
data collected on the day of treatment and six months post-treatment. In this analysis, the 
difference in benefit of ACR over ESP at 12 months included a confidence interval that 
marginally overlapped with the minimal clinically important difference of five points. 
Therefore, clinically meaningful group differences may potentially exist between ACR and 
ESP in the wider population. There were no meaningful differences observed in the OSS 
between the two surgical interventions of MUA and ACR at any time-point. Although 
diabetic patients had poorer outcomes compared with non-diabetic patients at all 
timepoints, there was no evidence of an effect of participants’ diabetes status, receipt of 
previous physiotherapy, baseline treatment preferences or length of frozen shoulder 
symptoms at baseline on the primary outcome.  
 
Serious complications were rare, although the ACR group was relatively less safe. Only two 
participants allocated to MUA had a serious complication. One of the participants in the ACR 
group diagnosed with a deep vein thrombosis actually received non-trial physiotherapy. 
There was, therefore, only a marginal difference in the safety profile between MUA and ESP 
for which in the latter group there were half the participants. Whilst no participants 
allocated to ESP had a serious complication, these participants were more likely to need 
further treatment. Participants in the ACR group received fewest further treatments.  
 
It is notable that the difference in OSS scores and the difference in health-related quality of 
life are in the same direction, with only a small difference in OSS scores and QALYs observed 
across groups. A possible trend of ACR group improving over time, which might continue 
with longer term follow up, could be explained by the timing of the delivery of the 
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interventions which has been examined and does not alter the interpretation of the findings 
of the primary analysis. We are confident that important costs, including costs of 
complications, have been captured during the trial follow-up. The strengths of this study 
were the pragmatic design, recruiting from 35 hospitals (including 90 surgeons and 285 
physiotherapists) across a range of rural and urban areas with minimal exclusions. This 
makes the results generalisable and applicable to clinical practice in the UK. There were low 
levels of attrition within and between groups in the completion of the extensively validated 
patient-reported primary outcome, which measures pain and impact of any stiffness on 
shoulder function.22 There was also limited cross-over. The statistical model used meant 
only six per cent of trial participants were not included in the primary analyses and 
consequently ensured we at least achieved the planned 90% statistical power. The results 
were robust to the sensitivity and sub-group analyses. Diagnosis of frozen shoulder can be 
challenging and there is no reference standard for comparison.6 As visual estimation of 
external rotation has fair to good reliability,13 restrictions (typically with pain) in both 
passive and active external rotation have been used as diagnostic criteria in clinical studies.7 
This helped to ensure correct diagnosis in our study population. We also focused on 
delivering good standards of care, with surgeons using techniques with which they were 
familiar, and most operations being conducted by consultant surgeons. Physiotherapy was 
delivered by qualified physiotherapists. Crucially, we standardised the physiotherapy 
pathway in all arms of the trial to reduce variations in care between participants and trial 
arms. All participants were provided with written advice detailing the home exercises they 
needed to perform.20  
 
The main limitation of the study was that participants who had ACR or MUA had to wait 
longer to receive their treatment. Our additional analysis incorporating different waiting 
times confirmed this did not influence the main trial results. For participants who started 
treatment, it was reassuring that the OSS was stable between baseline and start of 
treatment, but it is possible that only participants with a more resistant frozen shoulder had 
surgery. This analysis is also limited, as it reflects treatment effects at pragmatic follow-up 
times accounting for the different outcome trajectories, rather than observing what would 
have happened if all three trial treatments were delivered at similar times. Given the nature 
of the trial treatments, the blinding of participants and clinicians to treatment allocation 
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was not possible or desirable in this pragmatic trial. The lack of any sub-group effect of 
participant baseline treatment preferences on the OSS may in part mitigate concerns from a 
lack of blinding. A further potential threat to study validity was non-compliance with the 
treatments. However, the trial findings were consistent when analysed both as randomised 
(ITT) and with CACE analysis. Finally, only 6% of UK practitioners were using Hydrodilatation 
when we surveyed practice to inform the design of UK FROST and consequently this was not 
identified as a priority intervention for evaluation.10 Its popularity has increased since then 
and whilst there are recent small trials that have compared Hydrodilatation with MUA, ACR 
and intra-articular steroid injections,33 34 the evidence of Hydrodilatation’s effectiveness is 
inconclusive.  
 
In conclusion, all three treatments in our study led to significant improvements in patient-
reported shoulder pain and function. None of the treatments were clearly superior. ACR 
resulted in the least number of further treatments but carried higher risks and costs. The 
ESP pathway with steroid injection could be accessed quickly in the NHS, but more patients 
who had ESP needed further treatment. MUA was the most cost-effective option but with a 
longer waiting time to access than ESP. These findings should help clinicians discuss 
treatment options with patients during shared decision making and encourage surgeons to 
use ACR more selectively when less costly and less invasive interventions fail. 
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Characteristic MUA ACR ESP MUA ACR ESP 
Gender, n (%)       
Male 72 (36%) 77 (38%) 35 (35%) 68 (36%) 74 (39%) 31 (33%) 
Female 129 (64%) 126 (62%) 64 (65%) 121 (64%) 117 (61%) 62 (67%) 
Age (years)       
N 201 203 99 189 191 93 
Mean (SD) 54·5 (7.7) 53·9 (7.7) 54·5 (7·8) 54·4 (7·3) 54·4 (7·6) 54·8 (7·8) 
Median (IQR) 54 (54, 60) 54 (54, 59) 53 (53, 60) 54 (54, 60) 55 (55, 59) 53 (53, 60) 
Diabetic, n (%)       
No 141 (70%) 143 (70%) 69 (70%) 131 (69%) 135 (71%) 66 (71%) 
Type I 12 (6%) 12 (6%) 5 (5%) 12 (6%) 11 (6%) 5 (5%) 
Type II 48 (24%) 48 (24%) 25 (25%) 46 (24%) 45 (24%) 22 (24%) 
Affected shoulder, n 
(%) 
      
Left 127 (63%) 121 (60%) 56 (57%) 119 (63%) 114 (60%) 54 (58%) 
Right 73 (36%) 80 (39%) 43 (43%) 69 (37%) 75 (39%) 39 (42%) 
Missing 1 (1%) 2 (1%) 0 (0%) 1 (1%) 2 (1%) 0 (0%) 
Dominant arm 
affected, n (%) 
      
Yes 81 (40%) 82 (40%) 39 (39%) 77 (41%) 76 (40%) 36 (39%) 
No 115 (57%) 120 (59%) 59 (60%) 107 (57%) 114 (60%) 56 (60%) 
Ambidextrous 0 (0%) 1 (<0.5%) 0 (0%) 0 (0%) 1 (1%) 0 (0%) 
Missing 5 (2%) 0 (0%) 1 (1%) 5 (3%) 0 (0%) 1 (1%) 
Duration of symptoms 
(months) 
      
N 196 201 98 185 190 92 
Mean (SD) 10·5 (8·6) 11·3 (10·0) 10.8 (8·8) 10·7 (8·7) 11·3 (10·1) 11·0 (9·0) 
Median [IQR] 8 [6, 12] 9 [6, 12] 8 [6, 12] 8 [6, 12] 9 [6, 12] 8 [6, 12] 
min, max 2, 60 0, 96 2, 72 2, 60 2, 96 2, 72 
Duration of symptoms 
(grouped), n (%) 
      
< 9 months 103 (51%) 95 (47%) 51 (52%) 96 (51%) 90 (47%) 48 (52%) 
≥ 9 months 93 (46%) 106 (52%) 47 (47%) 89 (47%) 100 (52%) 44 (47%) 
Missing 5 (2%) 2 (1%) 1 (1%) 4 (2%) 1 (1%) 1 (1%) 
X-rays, n (%)       
Anteroposterior 
view  
200 (100%) 201 (99%) 99 (100%) 188 (99%) 190 (99%) 93 (100%) 
Axillary view 174 (87%) 179 (88%) 86 (87%) 163 (86%) 169 (88%) 80 (86%) 
Modified Axillary 29 (14%) 24 (12%) 14 (14%) 27 (14%) 24 (13%) 14 (15%) 
Employment status 
summary, n (%) 
      
In paid work 129 (64%) 118 (58%) 53 (54%) 124 (66%) 111 (58%) 50 (54%) 
Not in paid work 69 (34%) 82 (40%) 46 (46%) 62 (33%) 78 (41%) 43 (46%) 
Missing 3 (1%) 3 (1%) 0 (0%) 3 (2%) 2 (1%) 0 (0%) 
Type of employment, 
n (%)  
      
Unskilled manual 17 (8%) 15 (7%) 8 (8%) 16 (8%) 13 (7%) 7 (8%) 
Skilled manual  21 (10%) 18 (9%) 18 (18%) 19 (10%) 16 (8%) 17 (18%) 
Unskilled non-
manual 
19 (9%) 17 (8%) 4 (4%) 19 (10%) 17 (9%) 4 (4%) 
Skilled non-manual 41 (20%) 37 (18%) 13 (13%) 40 (21%) 37 (19%) 12 (13%) 
Professional 13 (6%) 19 (9%) 10 (10%) 13 (7%) 18 (9%) 10 (11%) 








Characteristic MUA ACR ESP MUA ACR ESP 
Currently taking 
steroids for affected 
shoulder, n (%) 
      
Yes 2 (1%) 7 (3%) 0 (0%) 2 (1%) 7 (4%) 0 (0%) 
No 196 (98%) 195 (96%) 99 (100%) 184 (97%) 183 (96%) 93 (100%) 
Missing 3 (1%) 1 (<0.5%) 0 (0%) 3 (2%) 1 (1%) 0 (0%) 
Had steroid injection 
for affected shoulder, 
n (%) 
      
Yes 97 (48%) 117 (58%) 55 (56%) 93 (49%) 112 (59%) 53 (57%) 
No 102 (51%) 86 (42%) 44 (44%) 94 (50%) 79 (41%) 40 (43%) 
Missing 2 (1%) 0 (0%) 0 (0%) 2 (1%) 0 (0%) 0 (0%) 
Previous physio-
therapy for affected 
shoulder, n (%) 
      
Yes 125 (62%) 124 (61%) 59 (60%) 117 (62%) 117 (61%) 58 (62%) 
No 76 (38%) 77 (38%) 39 (39%) 72 (38%) 73 (38%) 35 (38%) 
Missing 0 (0%) 2 (1%) 1 (1%) 0 (0%) 1 (1%) 0 (0%) 
Number of weeks had 
shoulder problem 
(median, [IQR]) 
32 [24-52] 35 [24-52] 32 [24-48] 34 [24-52] 35.5[24-52] 32 [24-48] 
Similar shoulder 
problem on the 
opposite side, n (%) 
      
Yes 62 (31%) 53 (26%) 13 (13%) 59 (31%) 51 (27%) 12 (13%) 
No 132 (66%) 146 (72%) 85 (86%) 124 (66%) 136 (71%) 80 (86%) 
Missing 7 (3%) 4 (2%) 1 (1%) 6 (3%) 4 (2%) 1 (1%) 
OSS (0-48)a       
N 201 203 99 189 191 93 
Mean (SD) 20·4 (8.9) 19·2 (7·7) 20·3 (8·0) 20·6 (8·9) 19·2 (7·5) 20·3 (8·1) 
Median 20 19 20 20 19 20 
IQR 14, 27 13, 25 15, 26 14, 27 14, 25 15, 26 
QuickDASH (0-100)       
N 192 197 96 181 187 90 
Mean (SD) 57·0 (21·0) 61·7 (18·5) 59·4 (19·7) 56·8 (21·1) 61·3 (18·5) 59·1 (20·0) 
Median 59 64 60 59 64 59·5 
IQR 42, 75 52, 75 46, 73 43, 73 50, 73 46, 73 
Pain NRS (0-10)       
N 199 201 99 187 190 93 
Mean (SD) 6·8 (2·2) 7·0 (1·9) 6·9 (2·4) 6·7 (2·3) 7·0 (1·9) 6·8 (2·4) 
Median 7 7 7 7 7 7 
IQR 5, 8 6, 8 5, 8 5, 8 6, 8 5, 8 
Symptom severity (0-
100) 
      
N 198 201 99 186 189 93 
Mean (SD) 83·8 (21·8) 86·2 (20·1) 89·2 (15·4) 83·9 (22·1) 86·0 (20·4) 89·0 (15·5) 
Median 90 95 100 90 95 100 
IQR 75, 100 80, 100 80, 100 80, 100 80, 100 80, 100 







Table 2: Further treatments 







Further surgical treatment    
ACR 7 0 5 
MUA 1 1 3 
Further non-surgical treatment    
Steroid injection 3 3 3 
Glenohumeral joint injection 2 0 0 
Ultrasound guided injection 0 1 1 
Other/Further physiotherapy 2 3 6 
Rheumatology clinic 0 0 1 
Total number of further treatments 15 8 19 
Total number of patients having one or 
more further treatments (% of 
randomised) 
14 (7%) 8 (4%) 15 (15%) 
27 
 
Table 3: Estimated mean outcome differences 
 









p-value Mean Difference 
(95% CI) 
p-value Mean Difference 
(95% CI) 
p-value 
OSSa          
3 months 30·2 26·9 31·6 -1·36 (-3·70 to 0·98) 0·25 -4·72 (-7·06 to -2·39) <0·01 -3·36 (-5·27 to -1·45) <0·01 
6 months 37·1 35·9 34·9 2·15 (-0·12 to 4·42) 0·06 0·98 (-1·31 to 3·26) 0·40 -1·17 (-3·02 to 0·67) 0·21 
12 monthsb 38·3 40·3 37·2 1·05 (-1·28 to 3·39) 0·38 3·06 (0·71 to 5·41) 0·01 2·01 (0·10 to 3·91) 0·04 
Average 35·2 34·4 34·6 0·61 (-1·31 to 2·53) 0·53 -0·23 (-2·15 to 1·70) 0·82 -0·84 (-2·41 to 0·72) 0·29 
OSS Time Adjustedc           
3 months 28·2 26·0 29·4 -1·18 (-3·10 to 0·73) 0·23 -3·33 (-5·25 to -1·40) 0·01 -2·14 (-3·71 to -0·57) 0·01 
6 months 32·5 31·5 32·7 -0·15 (-1·90 to 1·60) 0·87 -1·13 (-2·88 to 0·62) 0·21 -0·98 (-2·40 to 0·44) 0·18 
12 months 41·1 42·5 39·2 1·92 (-0·16 to 4·00) 0·07 3·26 (1·18 to 5·35) <0·01 1·35 (-0·33 to 3·02) 0·12 
EQ-5D-5Ld          
Baseline 0·46 0·43 0·40 0·05 (-0·01 to 0·12) 0·10 0·03 (-0·04 to 0·09) 0·42 -0·03 (-0·08 to 0·02) 0·28 
3 months 0·63 0·57 0·61 0·03 (-0·03 to 0·08) 0·38 -0·04 (-0·10 to 0·02) 0·18 -0·06 (-0·11 to -0·02) 0·01 
6 months 0·73 0·68 0·68 0·05 (-0·01 to 0·10) 0·10 -0·004 (-0·06 to 0·05) 0·88 -0·05 (-0·10 to -0·01) 0·02 
12 months 0·73 0·74 0·69 0·04 (-0·02 to 0·10) 0·20 0·05 (-0·02 to 0·10) 0·20 0·005 (-0·04 to 0·05) 0·85 
QuickDASHe           
3 months 38·8 44·4 37·1 1·77 (-3·41 to 6·96) 0·50 7·33 (2·16 to 12·49) 0·01 5·55 (1·32 to 9·78) 0·01 
6 months 27·7 27·4 29·2 -3·55 (-8·68 to 1·58) 0·18 -1·82 (-6·94 to 3·31) 0·49 1·73 (-2·39 to 5·86) 0·41 
12 months 29·9 18·2 23·4 -0·50 (-5·70 to 4·70) 0·85 -5·20 (-10·42 to 0·02) 0·05 -4·71 (-8·91 to -0·50) 0·03 
Pain NRSf           
3 months 4·1 4·7 3·7 0·43 (-0·17 to 1·03) 0·16 1·02 (0·42 to 1·61) <0·01 0·59 (0·10 to 1·07) 0·02 
6 months 2·8 2·8 3·0 -0·19 (-0·78 to 0·40) 0·53 -0·14 (-0·74 to 0·45) 0·63 0·05 (-0·43 to 0·52) 0·85 
12 months 2·4 1·7 2·5 -0·08 (-0·66 to 0·50) 0·78 -0·81 (-1·39 to -0·23) 0·01 -0·73 (-1·20 to -0·25) <0·01 
Extent of recoveryg h           
3 months 51·4 54·0 53·9 -2·55 (-11·68 to 6·58) 0·58 0·11 (-9·02 to 9·23) 0·98 2·66 (-4·84 to 10·15) 0·49 
6 months 31·9 34·7 38·6 -6·71 (-15·83 to 2·42) 0·15 -3·93 (-13·06 to 5·21) 0·40 2·78 (-4·50 to 10·06) 0·45 
12 months 27·3 21·2 26·9 0·46 (-7·79 to 8·70) 0·91 -5·65 (-13·91 to 2·61) 0·18 -6·11 (-12·86 to 0·64) 0·08 
a linear mixed covariance pattern model adjusted for age, gender, diabetes, OSS at baseline (fixed effects), and site (random effect) 
b primary endpoint for each treatment comparison 
c linear mixed random intercept model adjusted for age, gender, diabetes, OSS at baseline (fixed effects), and site (random effect) 
d Univariate generalised linear model, including group as a fixed effect factor and baseline EQ-5D-5L score as a covariate 
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e linear mixed covariance pattern model adjusted for age, gender, diabetes, Quick DASH at baseline (fixed effects), and site (random effect) 
f linear mixed covariance pattern model adjusted for age, gender, diabetes, Quick DASH at baseline (fixed effects), and site (random effect) 
g based on 0-100 VAS of perceived need for further treatment 





Table 4: Adverse Events by treatment arm as randomised (footnotes denote treatment as 
received, if different) 
 MUA ACR ESP 
Serious Adverse Events    
Attended A&E for visual disturbance; headache; heaviness 
and numbness of arm 
1a     
Chest Infection   1   
Decreased oxygen saturation   1   
Deep Vein Thrombosis   1b   
Elevated blood sugars (prolonging hospitalisation)   1   
Hypoglycaemic seizure whilst under anaesthetic   1   
Likely anterior dislocation   1c   
Patient noticed facial drooping / weakness after surgery   1   
Septic Joint Arthritis 1     
Stroke (3 months post-treatment)   1   
Total 2 8 0 
Non-Serious Adverse Events    
Additional diagnosis requiring further treatment 1     
Adverse reaction to concurrent medication   1   
Allergic reaction to dressing   1   
Chest infection 1     
Episode of inflammation 1     
Infection   1   
Injury to adjacent structures such as nerve, tendon, bone or joint 1 1c   
Ipsilateral face swelling, face flushed and neck and face hot 1     
Long head biceps tendon pain and rupture     1 
Neuropathic symptoms 1 2d   
Patient being investigated for neck problems   1   
Persistent pain   1 1 
Persistent pain requiring further treatment 1 1   
Persistent stiffness and pain requiring treatment 1     
Pins + needles to hand 1     
Post-procedural worsening of shoulder pain 3 3 1e 
Recurrent stiffness requiring further treatment     1e 
Supraspinatus tendinopathy     1 
Surgical site infection   1f   
Transient hyperglycaemia, steroid flare or joint sepsis following 
corticosteroid injection 
3g   
Total 15 13 5 
a Received ‘no trial treatment’ 
b Received ‘non-trial physiotherapy’  
c Received ‘MUA’ 
d One patient received ‘Other’ treatment (Subacromial decompression) 
e Received ‘ACR’ 
f One patient received ‘Other’ treatment (ACR without MUA) 
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